BRAF: which options do we have for these patients in second line?

11 / 22

BRAF INHIBITION IN mCRC
Historical response rate is <10% for cetuximab and iriniotecan with PFS of 2’4 months for the BRAF mt pts. Target HR 0’5 for PFS (m PFS 2’4 vs 4’8m).